Literature DB >> 32295798

Phlegmasia cerulea dolens in a patient treated with carboplatin.

Martin Söderman1,2, Peter Grimm3.   

Abstract

Phlegmasia cerulea dolens (PCD) is a rare, fulminant, potentially lethal and often debilitating presentation of deep venous thrombosis (DVT). Mortality and amputations rates are high. We present a rare case of bilateral PCD in the lower extremities. A 67-year-old woman presented with newly diagnosed squamous cell cancer of unknown primary origin with lymph node metastases to the neck. The patient started curatively intended treatment, consisting of removal of one lymph node on the neck, radiotherapy with concomitant carboplatin and nimorazol. The patient developed bilateral DVT in the legs. Despite treatment with low-molecular-weight heparins, the patient developed thrombosis in the inferior vena cava and lungs. Due to developing painful discolouration and necrosis on the legs, the patient underwent acute and extensive surgery. PCD is a severe and potentially lethal form of DVT. There are several known risk factors for developing DVT, including active cancer and the use of chemotherapy. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; surgery; venous thromboembolism

Mesh:

Substances:

Year:  2020        PMID: 32295798      PMCID: PMC7199177          DOI: 10.1136/bcr-2019-233760

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Short- and long-term results after thrombolytic treatment of deep venous thrombosis.

Authors:  J Schweizer; W Kirch; R Koch; H Elix; G Hellner; L Forkmann; A Graf
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

Review 2.  Treatment of acute iliofemoral deep vein thrombosis.

Authors:  Edward T Casey; M Hassan Murad; Magaly Zumaeta-Garcia; Mohamed B Elamin; Qian Shi; Patricia J Erwin; Victor M Montori; Peter Gloviczki; Mark Meissner
Journal:  J Vasc Surg       Date:  2012-03-21       Impact factor: 4.268

Review 3.  Trends in management of phlegmasia cerulea dolens.

Authors:  Khamin Chinsakchai; Kaj Ten Duis; Frans L Moll; Gert J de Borst
Journal:  Vasc Endovascular Surg       Date:  2011-01       Impact factor: 1.089

Review 4.  Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum.

Authors:  Mark H Meissner; Peter Gloviczki; Anthony J Comerota; Michael C Dalsing; Bo G Eklof; David L Gillespie; Joann M Lohr; Robert B McLafferty; M Hassan Murad; Frank Padberg; Peter Pappas; Joseph D Raffetto; Thomas W Wakefield
Journal:  J Vasc Surg       Date:  2012-04-01       Impact factor: 4.268

Review 5.  Thrombotic Risk from Chemotherapy and Other Cancer Therapies.

Authors:  M D Debbie Jiang; M D Alfred Ian Lee
Journal:  Cancer Treat Res       Date:  2019

Review 6.  Management of Post-Traumatic Phlegmasia Cerulea Dolens via Right-to-Left Femoral Vein to Femoral Vein Bypass (Palma Procedure).

Authors:  Anahita Dua; Jennifer Heller; Cheong Lee
Journal:  Vasc Endovascular Surg       Date:  2017-09-14       Impact factor: 1.089

Review 7.  Deep Venous Thrombosis.

Authors:  Mark Olaf; Robert Cooney
Journal:  Emerg Med Clin North Am       Date:  2017-08-23       Impact factor: 2.264

8.  Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer.

Authors:  Jorge D Ramos; Sarah K Holt; George R Schade; Matthew D Galsky; Jonathan L Wright; John L Gore; Evan Y Yu
Journal:  BJU Int       Date:  2019-02-19       Impact factor: 5.588

9.  Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.

Authors:  Eric S Kim; Andrea M Baran; Esther L Mondo; Thomas D Rodgers; Gradon C Nielsen; David W Dougherty; Kishan J Pandya; David Q Rich; Edwin van Wijngaarden
Journal:  PLoS One       Date:  2017-12-11       Impact factor: 3.240

Review 10.  Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview.

Authors:  Gerald Soff
Journal:  Cancer Treat Res       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.